2012 Tuberous Sclerosis Complex Clinical Trial Award Program
Page 2

With this, the funding agency requires the proposals to be submitted under this program to focus on the following areas:

a) The studies of the pathogenesis, disease severity prediction and diversity of symptoms that affects a patient's cognition, behavior, sleep, renal and pulmonary functions, along with the signs and symptoms of epilepsy and autism

b) The studies regarding the impact of TSC manifestations over the lifespan of a patient

c) The determination of novel strategies for the management and prevention of TSC manifestations including early therapeutic approaches

d) The deep comprehension of the cellular and molecular mechanisms of TSC developmental stages in mammalian and non-mammalian systems

e) Genetic, epigenetic, and non-genetic modifiers of TSC

f) The identification of biomarkers for early detection, prognosis, and prediction of TSC treatment outcomes.

To support this activities covered under this initiative, the Department of Defense is willing to administer funds in the amount of $1,600,000 per year, for a maximum project period of up to 4 years.

Assistant Professors or Lead Professors at Accredited Colleges and Universities are encouraged to submit an application under the 2012 Tuberous Sclerosis Complex Clinical Trial Award Program.

2012 Tuberous Sclerosis Complex Clinical Trial Award Program
  Back to Page 1

About The Author Iola Bonggay is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. She also maintains Websites providing resources on community grants and health grants.

Additional Resources

category - Health Grants

Small Business Innovation Research Phase IIB Bridge Awards
In line with this mission, the NIH has recently constituted the Small Business Innovation Research Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization Program.

---

Leadership Group for a Clinical Research Network on Antibacterial Resistance Program
In line with this mission, the National Institutes of Health has collaborated with the National Institute of Allergy and Infectious Diseases (NIAID) in an attempt to establish the Leadership Group for a Clinical Research Network on Antibacterial Resistance Program.

---

Minor Use Minor Species Development of Drugs: Research Project Grant
The National Institutes of Health has partnered with the U.S. Food and Drug Administration (FDA) and the Center for Veterinary Medicine(CVM) in an effort to establish the Minor Use Minor Species Development of Drugs: Research Project Grant.

---

HRSA: Reducing Loss to Follow-up after Failure to Pass Newborn Hearing Screening
Reducing to Loss of Follow-up after Failure to Pass Newborn Hearing Screening program enables eligible health care institutions to solicit funds by establishing project proposals that would greatly improve the number of infants receiving appropriate and timely follow-ups through the utilization of patient-centered interventions.

---